Royal Bank of Canada Raises Chemed (NYSE:CHE) Price Target to $667.00

Chemed (NYSE:CHE - Get Free Report) had its target price boosted by equities research analysts at Royal Bank of Canada from $633.00 to $667.00 in a report issued on Friday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Royal Bank of Canada's price target would suggest a potential upside of 10.14% from the stock's previous close.

Separately, StockNews.com raised shares of Chemed from a "hold" rating to a "buy" rating in a report on Friday, March 7th.

Chemed Price Performance

CHE traded down $2.45 on Friday, hitting $605.62. 96,441 shares of the stock were exchanged, compared to its average volume of 87,768. Chemed has a 12 month low of $512.12 and a 12 month high of $653.75. The business has a 50-day moving average of $563.45 and a two-hundred day moving average of $565.08. The firm has a market capitalization of $8.86 billion, a price-to-earnings ratio of 30.60, a PEG ratio of 2.15 and a beta of 0.43.

Insider Activity

In other news, VP Brian C. Judkins acquired 145 shares of the stock in a transaction dated Monday, December 30th. The stock was bought at an average price of $519.50 per share, with a total value of $75,327.50. Following the completion of the purchase, the vice president now directly owns 1,678 shares of the company's stock, valued at $871,721. This represents a 9.46 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $593.67, for a total transaction of $1,187,340.00. Following the sale, the chief executive officer now directly owns 102,679 shares of the company's stock, valued at $60,957,441.93. This represents a 1.91 % decrease in their position. The disclosure for this sale can be found here. 3.32% of the stock is currently owned by insiders.

Remove Ads

Institutional Trading of Chemed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its position in Chemed by 17.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 1,382 shares of the company's stock valued at $732,000 after purchasing an additional 207 shares during the period. Centaurus Financial Inc. increased its position in Chemed by 5.6% during the 4th quarter. Centaurus Financial Inc. now owns 5,354 shares of the company's stock valued at $2,837,000 after purchasing an additional 283 shares during the period. Cim LLC increased its position in Chemed by 2.2% during the 4th quarter. Cim LLC now owns 2,008 shares of the company's stock valued at $1,064,000 after purchasing an additional 44 shares during the period. Jefferies Financial Group Inc. increased its position in Chemed by 335.0% during the 4th quarter. Jefferies Financial Group Inc. now owns 1,453 shares of the company's stock valued at $770,000 after purchasing an additional 1,119 shares during the period. Finally, United Advisor Group LLC increased its position in Chemed by 25.1% during the 4th quarter. United Advisor Group LLC now owns 807 shares of the company's stock valued at $428,000 after purchasing an additional 162 shares during the period. Institutional investors and hedge funds own 95.85% of the company's stock.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.